Back to Search
Start Over
Virological response to initial antiretroviral regimens containing abacavir or tenofovir
- Source :
- The Journal of infectious diseases. 200(5)
- Publication Year :
- 2009
-
Abstract
- Patients with a baseline viral load >100,000 copies/mL receiving abacavir (ABC) as part of the nucleoside-backbone component of their first highly active antiretroviral therapy (HAART) regimen have been reported to have a greater failure rate than those receiving tenofovir (TDF). We analyzed short-term outcomes of the use of HAART combinations that included ABC or TDF. The mean 2-8-week change in viral load was calculated using linear regression. In total, 1136 patients started ABC, and 412 started TDF. After adjustment for baseline viral load and other factors, there was no difference in the change in viral load between the patients who started ABC and those who started TDF (0.03 [95% confidence interval, -0.07 to 0.12]) log copies/mL; P = .59). Furthermore, there was no evidence that this effect differed according to baseline viral load (P = .88 for the interaction between pre-HAART viral load and nucleoside started). Like-wise, there was no difference in rates of virological failure between the 2 drugs at 24-48 weeks after starting HAART.
- Subjects :
- Male
medicine.medical_specialty
Tenofovir
Anti-HIV Agents
Organophosphonates
HIV Infections
Drug resistance
Biology
Abacavir
Internal medicine
Antiretroviral Therapy, Highly Active
medicine
Immunology and Allergy
Humans
Treatment Failure
Reverse-transcriptase inhibitor
Adenine
Viral Load
Virology
Confidence interval
Dideoxynucleosides
Regimen
Infectious Diseases
Treatment Outcome
Cohort
HIV-1
Female
Viral load
medicine.drug
Subjects
Details
- ISSN :
- 00221899
- Volume :
- 200
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- The Journal of infectious diseases
- Accession number :
- edsair.doi.dedup.....e4810b7b92acabf8e29e7e6416a48320